Literature DB >> 24402605

The postresection alpha-fetoprotein in cirrhotic patients with hepatocellular carcinoma. An independent predictor of outcome.

Marc-Antoine Allard1, Antonio Sa Cunha, Aldrick Ruiz, Eric Vibert, Mylène Sebagh, Denis Castaing, René Adam.   

Abstract

BACKGROUND: The postresection alpha-fetoprotein (AFP) in cirrhotic patients with hepatocellular carcinoma (HCC) may predict overall survival (OS) and recurrence beyond Milan criteria (MC) among the subgroup of initially transplantable patients.
METHODS: All patients with cirrhosis resected for HCC between January 1990 and December 2010 in a single institution and presenting a serum AFP value > 15 ng/ml at diagnosis were included. The postresection AFP was analyzed as a dichotomized variable: normalization (norm + group) or not (norm - group) within the 90-day postresection period.
RESULTS: Among 271 resected patients, 141 patients (52%) had a level of serum AFP ≥ 15 ng/ml at diagnosis. Five-year OS and median survival were 42% and 52 months in group norm + versus 20% and 23 months in the group norm - (P = 0.009). On multivariate analysis, the absence of AFP normalization was an independent factor of poor OS as well as microvascular invasion, and satellites nodules. Among theoretically transplantable patients, independent predictors of recurrence beyond MC were the absence of AFP normalization (risk ratio (RR) 5.02 [1.53-16.34]) and microvascular invasion (RR 4.76 [1.42-15.34]).
CONCLUSION: The postresection AFP has an independent prognostic value. Transplantable patients resected for HCC without 90-day AFP normalization should be discussed for early liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24402605     DOI: 10.1007/s11605-013-2433-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  38 in total

Review 1.  Management of hepatocellular carcinoma.

Authors:  Janice N Cormier; K Tyson Thomas; Ravi S Chari; C Wright Pinson
Journal:  J Gastrointest Surg       Date:  2006-05       Impact factor: 3.452

2.  Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.

Authors:  Christophe Duvoux; Françoise Roudot-Thoraval; Thomas Decaens; Fabienne Pessione; Hanaa Badran; Tullio Piardi; Claire Francoz; Philippe Compagnon; Claire Vanlemmens; Jérome Dumortier; Sébastien Dharancy; Jean Gugenheim; Pierre-Henri Bernard; René Adam; Sylvie Radenne; Fabrice Muscari; Filomena Conti; Jean Hardwigsen; Georges-Philippe Pageaux; Olivier Chazouillères; Ephrem Salame; Marie-Noelle Hilleret; Pascal Lebray; Armand Abergel; Marilyne Debette-Gratien; Michael D Kluger; Ariane Mallat; Daniel Azoulay; Daniel Cherqui
Journal:  Gastroenterology       Date:  2012-06-29       Impact factor: 22.682

3.  Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC.

Authors:  Hidenori Toyoda; Takashi Kumada; Yuji Kaneoka; Yukio Osaki; Toru Kimura; Akira Arimoto; Hiroko Oka; Osamu Yamazaki; Takao Manabe; Fumihiro Urano; Hobyung Chung; Masatoshi Kudo; Takashi Matsunaga
Journal:  J Hepatol       Date:  2008-05-23       Impact factor: 25.083

4.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

5.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

6.  High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.

Authors:  Shian-Yang Peng; Wei J Chen; Po-Lin Lai; Yun-Ming Jeng; Jin-Chuan Sheu; Hey-Chi Hsu
Journal:  Int J Cancer       Date:  2004-10-20       Impact factor: 7.396

7.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Authors:  Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

8.  New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy.

Authors:  Stephen L Chan; Frankie K F Mo; Philip J Johnson; Edwin P Hui; Brigette B Y Ma; Wing M Ho; Kwok C Lam; Anthony T C Chan; Tony S K Mok; Winnie Yeo
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

9.  Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.

Authors:  Shuji Sumie; Ryoko Kuromatsu; Koji Okuda; Eiji Ando; Akio Takata; Nobuyoshi Fukushima; Yasutomo Watanabe; Masamichi Kojiro; Michio Sata
Journal:  Ann Surg Oncol       Date:  2008-03-07       Impact factor: 5.344

10.  α-fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma.

Authors:  Yun-Hsuan Lee; Chia-Yang Hsu; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Cheng-Yuan Hsia; Teh-Ia Huo
Journal:  J Gastrointest Surg       Date:  2012-11-28       Impact factor: 3.452

View more
  5 in total

1.  Preoperative and postoperative nomograms for predicting early recurrence of hepatocellular carcinoma without macrovascular invasion after curative resection.

Authors:  Yanfang Zhang; Xuezhong Lei; Liangliang Xu; Xiaoju Lv; Mingqing Xu; Hong Tang
Journal:  BMC Surg       Date:  2022-06-17       Impact factor: 2.030

2.  Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection.

Authors:  Narongsak Rungsakulkij; Wikran Suragul; Somkit Mingphruedhi; Pongsatorn Tangtawee; Paramin Muangkaew; Suraida Aeesoa
Journal:  World J Clin Cases       Date:  2018-06-16       Impact factor: 1.337

3.  Association of Postoperative Biomarker Response with Recurrence and Survival in Patients with Hepatocellular Carcinoma and High Alpha-Fetoprotein Expressions (>400 ng/ml).

Authors:  Lei Liang; Ming-Da Wang; Yao-Ming Zhang; Wan-Guang Zhang; Cheng-Wu Zhang; Wan Yee Lau; Feng Shen; Timothy M Pawlik; Dong-Sheng Huang; Tian Yang
Journal:  J Hepatocell Carcinoma       Date:  2021-03-12

4.  Predictors, Presentation, and Treatment Outcomes of Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Large Single Center Experience.

Authors:  Sirina Ekpanyapong; Neil Philips; Bao-Li Loza; Peter Abt; Emma E Furth; Rashmi Tondon; Vandana Khungar; Kim Olthoff; Abraham Shaked; Maarouf A Hoteit; K Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2019-11-22

5.  Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection.

Authors:  Narongsak Rungsakulkij; Wikran Suragul; Somkit Mingphruedhi; Pongsatorn Tangtawee; Paramin Muangkaew; Suraida Aeesoa
Journal:  Infect Agent Cancer       Date:  2018-06-08       Impact factor: 2.965

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.